文章：

CDK4/6抑制剂对肿瘤免疫的双重效应

The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity

原文发布日期：15 December 2025

DOI: 10.3390/cancers17243997

类型: Article

开放获取: 是

英文摘要：

CDK4/6 inhibitors exert effective anti-tumor effects by blocking the cell cycle and, as a result, have become vital in the systemic treatment of malignant tumors. Previous research has indicated that CDK4/6 inhibitors not only exert effects on the cell cycle but also have regulatory roles in tumor immunity, although the research findings are controversial. This study comprehensively summarizes the molecular mechanisms by which CDK4/6 inhibitors activate or suppress anti-tumor immunity and reveals the dual effects of CDK4/6 inhibitors on influencing interferon signaling, mediating senescence, and altering certain immune cells. In addition, the results of clinical trials of CDK4/6 inhibitors combined with immunotherapy are thought-provoking, with the severe adverse events that occur after treatment being the main factor affecting their therapeutic effect. Therefore, the future direction of this combined treatment strategy deserves further exploration.

摘要翻译： 

CDK4/6抑制剂通过阻断细胞周期发挥有效的抗肿瘤作用，因而在恶性肿瘤的系统性治疗中占据重要地位。既往研究表明，CDK4/6抑制剂不仅作用于细胞周期，对肿瘤免疫亦具有调控作用，但相关研究结论尚存争议。本研究系统综述了CDK4/6抑制剂激活或抑制抗肿瘤免疫的分子机制，揭示了该类药物通过影响干扰素信号通路、介导细胞衰老及改变特定免疫细胞状态所产生的双重免疫调节作用。此外，CDK4/6抑制剂联合免疫治疗的临床试验结果引人深思，治疗后出现的严重不良事件是影响其疗效的主要因素，故该联合治疗策略的未来发展方向值得深入探索。

原文链接：

The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity